Research
Hormonal
Tirzepatide is the only obesity management medication shown to significantly reduce the Apnea-Hypopnea Index (AHI) and achieve remission of Obstructive Sleep Apnea Syndrome (OSAS) in patients with obesity.
If you have obesity and sleep apnea, Tirzepatide has been shown to significantly reduce the severity of your sleep apnea (AHI) and can lead to remission of the condition. This is a unique benefit not clearly demonstrated by other weight loss drugs in this review.
ModerateSupportsMEDIUM confidence
Tirzepatide was effective in remission of obstructive sleep apnea syndrome... reporting a reduction of the Apnea-Hypopnea Index (AHI)... and a higher percent reduction of AHI
Why this rating
Based on only one RCT for OSAS.
Source
A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults
Barbara McGowan et al. · Nature Medicine · 2025
DOI 10.1038/s41591-025-03978-z
Meta-analysis · 56 studiesCited 47×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide and semaglutide are the only obesity management medications (OMMs) achieving greater than 10% total body weight loss (TBWL) at study endpoints, with tirzepatide uniquely associated with a significantly higher proportion of patients achieving ≥25% TBWL.Strong
- Semaglutide significantly reduces Major Adverse Cardiovascular Events (MACE) and hospitalization for heart failure (HHF) risk, while Tirzepatide significantly reduces HHF risk, offering cardiovascular protection beyond weight loss.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →